A recent article on the most read genomics news website, has featured an interview with Cyclomics founders Alessio Marcozzi and Jeroen de Ridder. The news item – which can be read in full on GenomeWeb – provides a comprehensive overview of the CyclomicsSeq technology for detection of cancer mutations in circulating tumor DNA. The article further describes the current Cyclomics company structure as well as the plans towards clinical validation of CyclomicsSeq technology in the context of treatment response monitoring and detection of recurring disease in head and neck cancer patients.